Famciclovir for Recurrent Genital Herpes
For treating recurrent genital herpes in healthy adults, use famciclovir 1000 mg twice daily for 1 day, initiated at the first sign of prodrome or lesions. 1
Episodic Treatment Regimens
The FDA-approved dosing for episodic treatment of recurrent genital herpes is famciclovir 1000 mg twice daily for a single day 1. This ultra-short course regimen is supported by CDC guidelines from 1998, which list famciclovir 125 mg twice daily for 5 days as an alternative option 2.
Key timing consideration: Treatment must be initiated within 6 hours of symptom onset for optimal efficacy 1. The FDA label explicitly states that efficacy when initiated more than 6 hours after onset has not been established. Patients should be provided with a prescription in advance so they can self-initiate therapy at the first sign of prodrome (tingling, itching, burning, pain) or lesions 2.
Alternative Episodic Dosing
While the 1-day regimen is preferred for convenience and compliance, research supports that famciclovir 125 mg twice daily for 5 days is equally effective 3. A clinic-initiated trial demonstrated that 125 mg, 250 mg, and 500 mg twice daily for 5 days all showed comparable efficacy in reducing viral shedding duration, symptom duration, and accelerating lesion healing, with the 125 mg dose being the lowest effective option 3.
Suppressive Therapy
For chronic suppression of frequent recurrences (≥6 episodes per year), use famciclovir 250 mg twice daily 1. This regimen reduces recurrence frequency by ≥75% 2.
Important Limitations for Suppressive Therapy
Duration restriction: The FDA label and 1998 CDC guidelines note that safety and efficacy beyond 1 year have not been established 1, 2. After 1 year of continuous suppression, discontinuation should be discussed to reassess recurrence rates, as frequency naturally decreases over time in many patients 2.
Once-daily dosing is less effective: Research demonstrates that famciclovir 250 mg once daily provides inferior suppression compared to twice-daily dosing 4. The median time to first recurrence was significantly longer with 250 mg twice daily (>120 days) versus 125 mg once daily (114 days) or placebo (82 days) 4.
Renal Impairment Adjustments
Dosage must be adjusted based on creatinine clearance (CrCl) 1:
For Episodic Treatment (1000 mg BID x 1 day regimen):
- CrCl ≥60 mL/min: 1000 mg every 12 hours
- CrCl 40-59 mL/min: 500 mg every 12 hours
- CrCl 20-39 mL/min: 500 mg as a single dose
- CrCl <20 mL/min: 250 mg as a single dose
- Hemodialysis: 250 mg as a single dose following each dialysis
For Suppressive Therapy (250 mg BID):
- CrCl ≥40 mL/min: 250 mg every 12 hours
- CrCl 20-39 mL/min: 125 mg every 12 hours
- CrCl <20 mL/min: 125 mg every 24 hours
- Hemodialysis: 125 mg following each dialysis
Critical safety note: Acute renal failure has been reported in patients with underlying renal disease who received inappropriately high doses for their level of renal function 1. The pharmacokinetic profile shows that in severe renal impairment (CrCl <30 mL/min), the area under the curve is approximately 10-fold higher and elimination is 4-fold slower than in normal renal function 5.
HIV-Infected Patients
For HIV-infected adults with recurrent genital herpes, use famciclovir 500 mg twice daily for 7 days 1. This longer, higher-dose regimen is necessary because immunocompromised patients may have prolonged episodes with more extensive disease 2. Treatment should be initiated within 48 hours of symptom onset 1.
Clinical Pearls and Pitfalls
Patient counseling is essential: Provide patients with a prescription to keep on hand so they can self-initiate treatment immediately at prodrome onset. The narrow 6-hour window for optimal efficacy means any delay in obtaining medication significantly reduces treatment benefit 1.
Resistance concerns: Unlike concerns with acyclovir, suppressive famciclovir therapy has not been associated with emergence of clinically significant resistance among immunocompetent patients 2.
Comparative safety: Famciclovir may be safer than acyclovir in patients with renal concerns. A population-based study found no increased risk of acute kidney injury with oral acyclovir compared to famciclovir 6, though famciclovir has been successfully used as an alternative in patients who developed renal dysfunction on acyclovir 7.
Convenience advantage: The 1-day episodic regimen and twice-daily suppressive dosing offer superior convenience compared to acyclovir's 5-times-daily episodic dosing or 3-times-daily suppressive regimen, which may improve adherence 2.